Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALDX
DateTimeSourceHeadlineSymbolCompany
08/05/202412:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202412:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202412:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202411:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202412:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202422:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202412:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
21/12/202321:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202312:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
18/12/202321:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
28/11/202312:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
27/11/202321:07Business WireAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202320:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202320:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
01/11/202311:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
01/11/202311:05Business WireAldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
16/10/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
27/09/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
26/09/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
19/09/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
12/09/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
11/09/202322:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
29/08/202310:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
24/08/202321:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALDX